Q4 FY2024 · ended Dec 31, 2024 · Revenue $3,000, -99.2% YoY · Filed Jun 16, 2026
Pulmatrix, Inc. (PULM) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$3,000
-99.2% vs prior quarter
Net income
$-1.04M
+33.1% vs year-ago quarter
Operating cash flow
$-1.11M
+41.3% vs year-ago quarter
Free cash flow
$-1.26M
+58.8% vs prior quarter
EPS
$-0.29
+31.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
3.65M
+0.0% vs year-ago quarter
Net cash
—
Operating margin
-65066.7%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PULM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1574235
- Former names
- Ruthigen, Inc. (until Jun 16, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.0M | -$1.3M | -$908,000 | -$866,000 | -$1.5M |
| Net income | -$1.0M | -$1.2M | -$928,000 | -$877,000 | -$1.5M |
| Diluted EPS | -$0.29 | -$0.32 | -$0.25 | -$0.24 | -$0.42 |
| Operating cash flow | -$1.1M | -$1.1M | -$706,000 | -$1.0M | -$1.9M |
| Total assets | $3.2M | $4.5M | $4.1M | $5.0M | $6.2M |
| Total liabilities | $689,000 | $905,000 | $329,000 | $249,000 | $548,000 |
| Stockholders' equity | $2.6M | $3.6M | $3.8M | $4.7M | $5.6M |
| Cash and investments | $2.2M | $3.3M | $4.1M | $4.8M | $5.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 27, 2026 | Oct 26, 2026 |
| ARS | Annual report to shareholders | Oct 5, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-K/A | Amended annual report | Jun 16, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 652 Pulmatrix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.